# Forest biopharma & phytochemicals Forest- and plant-derived pharmaceutical compounds and phytochemicals — paclitaxel from Taxus, curcumin, aged-black-garlic and standardized botanical extracts — produced by Phyton Biotech, Indena, Sabinsa, Natural Remedies and Pharmactive. Source: https://en.bioecon.ru/technology/forest-biopharma-phytochemicals/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: EU pharma & Novel Food legislation | OECD: Biotech & health | Regulator: FDA (USA), EFSA/EMA (EU), NMPA (China)] Forest biopharma & phytochemicals is the industry that turns forest and medicinal plants into pharmaceutical actives and standardized botanical ingredients. Phyton Biotech (Germany) produces paclitaxel by plant cell fermentation rather than yew-tree harvest, advancing sustainable taxane bioproduction; Indena (Italy, founded 1921) is a long-standing botanical-extract leader with a taxane-derivative process improving paclitaxel recovery from *Taxus baccata*; Sabinsa (USA) won Great-Britain Novel Food authorization for its Curcumin C3 Reduct® curcuminoid; Natural Remedies (India) runs an Animal Healthcare Innovation Center around Siddha-based herbal actives for veterinary use; and Pharmactive (Spain) supplies the clinically-studied ABG10+® aged-black-garlic and affron® saffron extracts. The route spans plant sourcing, solvent extraction, phytochemical standardization and clinical-grade evidence. The key directions of forest biopharma & phytochemicals are: 1. **Taxane biosynthesis (Taxane Biosynthesis):** paclitaxel and taxane API via plant cell fermentation and *Taxus* extraction (Phyton Biotech, Indena). 2. **Botanical solvent extraction (Botanical Solvent Extraction):** standardized botanical active-ingredient extraction (Indena, Pharmactive). 3. **Phytochemical standardization (Phytochemical Standardization):** marker-based standardization of curcuminoid/garlic/saffron actives (Sabinsa, Pharmactive). 4. **Plant cell fermentation (Plant Cell Fermentation):** cultivation of plant cells in bioreactors to produce forest-plant actives without harvesting the tree (Phyton Biotech). ### Sectoral value chain ``` [forest / medicinal plant (Taxus, Curcuma, garlic, saffron)] ──> [biomass harvest / cell culture] ──> [extraction] │ (purification & standardization) │ ▼ [drug / supplement ingredient] <─── [clinical evidence & formulation] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Plant sourcing** | forest / medicinal plants or plant cell cultures as feedstock | **In:** plant biomass / cell line. **Out:** raw botanical. | | **Extraction** | solvent extraction (or cell-fermentation harvest) of crude actives | **In:** raw botanical. **Out:** crude extract. | | **Purification** | purification to a standardized phytochemical active | **In:** crude extract. **Out:** standardized active. | | **Standardization** | marker-based standardization to clinical-grade actives | **In:** standardized active. **Out:** API / ingredient. | | **Clinical evidence** | clinical substantiation of the active's effect | **In:** active. **Out:** evidence dossier. | | **Formulation** | formulation into drug or supplement dosage forms | **In:** API, dossier. **Out:** drug / supplement. | Cross-cutting technologies of the sector: - **Plant cell fermentation (Plant Cell Fermentation):** bioreactor plant-cell cultures producing forest-plant actives without tree harvest (Phyton Biotech paclitaxel). - **Marker-based standardization (Marker-Based Standardization):** quantifying marker compounds (curcuminoids, allicin, saffron crocins) for reproducible actives. - **Taxane recovery (Taxane Recovery):** improved *Taxus* paclitaxel recovery processes (Indena taxane-derivative patent). --- ## US The United States contributes curcumin and botanical-ingredient standardization plus the FDA botanical-drug pathway. ### Sabinsa, FDA botanical drug guidance - **Sabinsa:** developed Curcumin C3 Reduct® curcuminoids and secured Great-Britain Novel Food authorization, advancing standardized turmeric phytochemicals for the nutrition market. - **FDA botanical guidance:** the FDA botanical drug development pathway frames US approval of plant-derived therapeutics. - **Standardization base:** US botanical-ingredient firms anchor marker-based standardization for supplement and drug use. --- ## CN China's traditional-medicine heritage anchors a large plant-derived pharma base, though corporate-specific 2026 facts were not pursued in this batch. ### Traditional Chinese Medicine phytochemical base - **TCM phytochemical base:** China's traditional-medicine industry supplies a large volume of plant-derived phytochemical actives (artemisinin, paclitaxel precursors, ginsenosides) under NMPA oversight and WHO traditional-medicine frameworks. - **Caveat:** this batch did not draft a specific Chinese firm candidate; the CN block is qualitative. - **Regulatory frame:** NMPA governs plant-derived drugs and traditional-medicine products in China. --- ## EU Europe is the global anchor for botanical-extract API and taxane bioproduction. ### Phyton Biotech, Indena, Pharmactive - **Phyton Biotech (Germany):** produces paclitaxel by plant cell fermentation, advancing sustainable taxane bioproduction that decouples the API from yew-tree harvest. - **Indena (Italy, founded 1921):** a long-standing botanical-extract leader with a taxane-derivative process improving paclitaxel recovery from *Taxus baccata*. - **Pharmactive (Spain):** supplies clinically-studied ABG10+® aged-black-garlic and affron® saffron phytochemical extracts for the supplement market. - **EU pharma & Novel Food:** EU pharmaceutical legislation and the Novel Food framework frame European plant-derived drugs and botanical ingredients. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Phyton Biotech** | 🇩🇪 Germany | *paclitaxel (plant cell fermentation)* | Taxus cell-culture taxane API | Commercial | | **Indena** | 🇮🇹 Italy | *botanical extracts / taxanes* | *Taxus baccata* paclitaxel recovery, founded 1921 | Commercial | | **Sabinsa** | 🇺🇸 USA | *Curcumin C3 Reduct®* | curcuminoid Novel Food GB authorization | Commercial | | **Natural Remedies** | 🇮🇳 India | *herbal / veterinary botanicals* | Siddha, Animal Healthcare Innovation Center | Commercial | | **Pharmactive** | 🇪🇸 Spain | *ABG10+ black garlic, affron saffron* | clinically-studied phytochemical extracts | Commercial | --- ## Tech stack and innovations The stack pairs plant sourcing and extraction with phytochemical standardization and clinical-grade evidence. 1. **Taxane biosynthesis (Taxane Biosynthesis):** - Phyton Biotech grows Taxus plant cells in fermenters to produce paclitaxel without harvesting yew trees; Indena improves *Taxus baccata* paclitaxel recovery via its taxane-derivative process. 2. **Botanical solvent extraction (Botanical Solvent Extraction):** - Indena and Pharmactive extract standardized botanical actives (taxanes, aged-black-garlic allicin, saffron crocins) for pharma and supplement use. 3. **Phytochemical standardization (Phytochemical Standardization):** - Sabinsa and Pharmactive standardize marker compounds (curcuminoids, ABG10+ markers) to reproducible clinical-grade actives, supported by Novel Food and clinical substantiation. --- ## Value chains and production pipelines ### Industrial pipeline of forest phytochemicals (FDA / EU pharma / NMPA frameworks) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Plant sourcing │ ───> │ 2. Extraction │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Standardization │ <─── │ 3. Purification │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Clinical evidence │ ───> │ 6. Formulation │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Plant sourcing Forest or medicinal plants (or plant cell cultures) supply the botanical feedstock; the output is raw botanical biomass or a cell-culture harvest. #### Stage 2: Extraction The biomass is solvent-extracted (or the cell culture harvested) to recover the crude active fraction; the output is a crude extract. #### Stage 3: Purification The crude extract is purified toward the phytochemical active of interest; the output is a purified active. #### Stage 4: Standardization The active is marker-standardized to a reproducible clinical-grade phytochemical API or ingredient; the output is a standardized active. #### Stage 5: Clinical evidence The standardized active is substantiated with clinical/analytical evidence (e.g. Pharmactive ABG10+ fingerprinting); the output is an evidence dossier. #### Stage 6: Formulation The active is formulated into drug or supplement dosage forms under FDA / EU pharma / NMPA frameworks; the output is a marketable forest-phytochemical product.